Screener
Castle Biosciences CSTL Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from exercise of common stock options | 322 | 18 |
| Payment of employees’ taxes on vested restricted stock units and performance-based restricted stock units | (6,598) | (2,515) |
| Proceeds from contributions to the employee stock purchase plan | 1,267 | 970 |
| Repayment of principal portion of finance lease liabilities | (24) | (26) |
| Net cash used in financing activities | (5,033) | (1,553) |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | (52,965) | (30,020) |
| Beginning of period | 116,729 | 119,709 |
| End of period | $63,764 | $89,689 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's financing cash flow?
- Castle Biosciences (CSTL) reported financing cash flow of -$5.03M in Q1 2026.
- How has Castle Biosciences's financing cash flow changed year-over-year?
- Castle Biosciences's financing cash flow decreased by 224.1% year-over-year, from -$1.55M to -$5.03M.
- What is the long-term trend for Castle Biosciences's financing cash flow?
- Over 2 years (2021 to 2025), Castle Biosciences's financing cash flow has grown at a 14.1% compound annual growth rate (CAGR), from $5.42M to -$7.06M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Castle Biosciences's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude